High--throughput screening of FDA--approved drugs identifies novel immunomodulatory agents for immune-mediated skin diseases

被引：0

作者：

Ghorbanalipoor, S. ^{[1
]}

Matsumoto, K. ^{[1
]}

Heimberg, L. ^{[1
]}

Krause, M. ^{[1
]}

Veldkamp, W. ^{[2
]}

Magens, M. ^{[1
]}

Zanken, J. ^{[1
]}

Vidarsson, G. ^{[3
,4
]}

Visser, R. ^{[3
,4
]}

Kuenzel, S. ^{[5
]}

Recke, A. ^{[6
,7
]}

Samavedam, U. ^{[1
]}

Gupta, Y. ^{[1
]}

Zillikens, D. ^{[6
,7
]}

Bieber, K. ^{[1
]}

Ludwig, R. J. ^{[1
]}

机构：

[1] Univ Lubeck, D-23562 Lubeck, Germany

[2] Radboudumc, Univ Clin, Nijmegen, Netherlands

[3] Sanquin Res, Amsterdam, Netherlands

[4] Landsteiner Lab, Amsterdam, Netherlands

[5] Max Planck Inst Evolutionary Biol, Plon, Germany

[6] Univ Lubeck, Dept Dermatol, D-23562 Lubeck, Germany

[7] Ctr Res Inflammat Skin, D-23562 Lubeck, Germany

来源：

EXPERIMENTAL DERMATOLOGY | 2023年 / 32卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

P094

引用

页码：E46 / E46

页数：1

共 50 条

[1] High-throughput Screening of FDA-approved Drugs Identifies Novel Inhibitors of Macropinocytosis
Lin, Hui-Ping
Ghoshal, Pushpankur
Singla, Bhupesh
Faulkner, Jessica L.
Shaw, Mary C.
O'Connor, Paul M.
She, Jin-Xiong
de Chantemele, Eric J. Belin
Csanyi, Gabor
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2018, 38
[2] The plethora of immunomodulatory drugs: opportunities for immune-mediated kidney diseases
Odler, Balazs
Tieu, Johanna
Artinger, Katharina
Chen-Xu, Michael
Arnaud, Laurent
Kitching, Richard A.
Terrier, Benjamin
Thiel, Jens
Cid, Maria C.
Rosenkranz, Alexander R.
Kronbichler, Andreas
Jayne, David R. W.
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, : II19 - II28
[3] HIGH-THROUGHPUT SCREENING OF FDA-APPROVED COMPOUNDS IN GLIOMA AND GLIOBLASTOMA IDENTIFIES NOVEL THERAPEUTICS
Wroblewski, Tadeusz
Tatman, Philip
Fringuello, Anthony
Scherer, Sam
Foreman, William
Damek, Denise
Youssef, Samy
Lillehei, Kevin
Ormond, David
Graner, Michael
NEURO-ONCOLOGY, 2021, 23 : 78 - 78
[4] A High-Throughput Screening Platform Identifies FDA-Approved Drugs That Inhibit SREBP Pathway Activation
T. Ishida, Chiaki
Kubota, Casie S.
Carlyle, Evan
Tsukamoto, Takashi
Espenshade, Peter J.
ACS CHEMICAL BIOLOGY, 2024, 19 (08) : 1695 - 1704
[5] Direct Effects of Immunomodulatory Agents on Podocytes in Immune-Mediated Glomerular Diseases
Manabe, Shun
Nitta, Kosaku
Nagata, Michio
RECENT ADVANCES IN THE PATHOGENESIS AND TREATMENT OF KIDNEY DISEASES, 2018, 195 : 131 - 142
[6] Screening FDA-approved drugs in a zebrafish model of ocular trauma identifies novel cytoprotectants
Eroglu, Arife
Nelson, Jeffrey Jeff
Malapani-Scala, Aurel
Mumm, Jeff S.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
[7] HIGH-THROUGHPUT DRUG SCREENING OF FDA-APPROVED ANTINEOPLASTIC DRUGS FOR THE TREATMENT OF AGGRESSIVE MENINGIOMAS
Jungwirth, Gerhard
Yu, Tao
Liu, Fang
Warta, Rolf
Unterberg, Andreas
Herold-Mende, Christel
NEURO-ONCOLOGY, 2019, 21 : 70 - 70
[8] HIGH-THROUGHPUT DRUG SCREENING OF FDA-APPROVED ANTINEOPLASTIC DRUGS FOR THE TREATMENT OF AGGRESSIVE MENINGIOMAS
Jungwirth, Gerhard
Yu, Tao
Liu, Fang
Warta, Rolf
Unterberg, Andreas
Herold-Mende, Christel
NEURO-ONCOLOGY, 2020, 22 : 68 - 68
[9] High throughput screening identifies repurposable drugs for modulation of innate and acquired immune responses
Ghorbanalipoor, Saeedeh
Matsumoto, Kazuko
Gross, Natalie
Heimberg, Linda
Krause, Malin
Veldkamp, Wendelien
Magens, Moritz
Zanken, Johannes
Neuschutz, Kerstin J.
De Luca, David A.
Kridin, Khalaf
Vidarsson, Gestur
Chakievska, Lenche
Visser, Remco
Kunzel, Sven
Recke, Andreas
Gupta, Yask
Boch, Katharina
Vorobyev, Artem
Kalies, Kathrin
Manz, Rudolf A.
Bieber, Katja
Ludwig, Ralf J.
JOURNAL OF AUTOIMMUNITY, 2024, 148
[10] Shedding Light on Novel Pathogenic and Therapeutic Aspects Related to Immune-Mediated Skin Diseases
Chiricozzi, Andrea
Girolomoni, Giampiero
VACCINES, 2023, 11 (04)

← 1 2 3 4 5 →